Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 4/20 | 0.47 |
| ▸ | RUNX1 | Q01196 | 2/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | GPR3 | P46089 | 2/20 | 0.36 |
| ▸ | ALPL | P05186 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | IL1B | P01584 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5438286 | 0.76 | CRHR1 (0.45) | CRHR1RUNX1SCN9AGPR3ABL1 | |
| SCHEMBL4626672 | 0.75 | CRHR1 (0.48) | CRHR1RUNX1SCN9AGPR3 | |
| SCHEMBL4878756 | 0.74 | CRHR1 (0.55) | CRHR1RUNX1SCN9AGPR3 | |
| SCHEMBL6343532 | 0.74 | CRHR1 (0.55) | CRHR1RUNX1SCN9AGPR3P2RX7 | |
| SCHEMBL6286387 | 0.73 | CRHR1 (0.61) | CRHR1RUNX1SCN9AGPR3 | |
| SCHEMBL4884652 | 0.73 | CRHR1 (0.46) | CRHR1RUNX1SCN9AGPR3ABL1 | |
| SCHEMBL6344985 | 0.73 | CRHR1 (0.47) | CRHR1RUNX1SCN9AGPR3ALPL | |
| SCHEMBL4882817 | 0.72 | CRHR1 (0.59) | CRHR1RUNX1SCN9AGPR3 | |
| SCHEMBL6602770 | 0.71 | CRHR1 (0.54) | CRHR1RUNX1SCN9A | |
| SCHEMBL4882797 | 0.71 | CRHR1 (0.56) | CRHR1SCN9AP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1734820-A4 | IMIDAZOPYRAZINES, IMIDAZOPYRIDINES, AND IMIDAZOPYRIMIDINES AS CRF1 RECEPTOR LIGANDS | NEUROGEN CORP (US) | 2008-01-23 | — | — | EP | disclosed |
| US-20080015196-A1 | Imidazopyrazines, Imidazopyridines, and Imidazopyrimidines as Crf1 Receptor Ligands | NEUROGEN CORPORATION (US) | 2008-01-17 | — | — | US | disclosed |
| US-20080015196-A1 | Imidazopyrazines, Imidazopyridines, and Imidazopyrimidines as Crf1 Receptor Ligands | NEUROGEN CORPORATION (US) | 2008-01-17 | — | — | US | disclosed |
| US-20080015196-A1 | Imidazopyrazines, Imidazopyridines, and Imidazopyrimidines as Crf1 Receptor Ligands | NEUROGEN CORPORATION (US) | 2008-01-17 | — | — | US | disclosed |
| EP-1734820-A2 | IMIDAZOPYRAZINES, IMIDAZOPYRIDINES, AND IMIDAZOPYRIMIDINES AS CRF1 RECEPTOR LIGANDS | Neurogen Corporation (US) | 2006-12-27 | — | — | EP | disclosed |
| WO-2005115399-A2 | IMIDAZOPYRAZINES, IMIDAZOPYRIDINES, ANS IMIDAZOPYRIMIDINES AS CRF1 RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015196-A1 | Imidazopyrazines, Imidazopyridines, and Imidazopyrimidines as Crf1 Receptor Ligands | CRHR1, CRHR2, CRHBP | CRHR1 1/4885RUNX1 1849/4885SCN9A 4698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.